Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B

Zoetis Inc.

2022-FY EPS reported $4.49 revenue$8,080,000,000

Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).
Full year 2022 revenue $8.1B (+4% reported, +8% operational); adj. net income $2.3B ($4.88 adj. EPS).
U.S. segment revenue $1.112B (+7%), driven by Simparica Trio and dermatology brands Apoquel and Cytopoint.
International segment revenue $901M (flat reported, +12% operational), led by parasiticides and dermatology.
FY23 guidance: revenue $8.575-8.725B (6-8% operational growth); adj. diluted EPS $5.34-5.44.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zoetis Inc. reported Full Year 2023 results: revenue $8.575 - $8.725 Billion, EPS $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis. Guidance initiated.

Period: Full Year 2023
Revenue: $8.575 - $8.725 Billion
EPS: $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis
Guidance: initiated
Result: guidance update

Exact text from the filing

Provides Full Year 2023 Revenue Guidance of $8.575 - $8.725 Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zoetis Inc. reported Full Year 2022 results: revenue $8.1 Billion, net income $2.1 Billion, or $4.49 per Diluted Share.

Period: Full Year 2022
Revenue: $8.1 Billion
Net income: $2.1 Billion, or $4.49 per Diluted Share
Result: reported results

Exact text from the filing

For Full Year 2022, Zoetis Reports Revenue of $8.1 Billion, Growing 4%, and Net Income of $2.1 Billion, or $4.49 per Diluted Share, on a Reported Basis

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zoetis Inc. reported the fourth quarter and full year 2022 results: revenue $2.0 Billion, net income $461 Million, or $0.99 per Diluted Share. Guidance initiated.

Period: the fourth quarter and full year 2022
Revenue: $2.0 Billion
Net income: $461 Million, or $0.99 per Diluted Share
Guidance: initiated
Result: reported results

Exact text from the filing

specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Reports Fourth Quarter and Full Year 2022 Results • For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis ◦ Delivers 9% Operational Growth in Revenue and 27% Operational Growth in Adjusted

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Zoetis Inc. filing history →

Source: SEC EDGAR

accession 0001555280-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.